Medical Uses of Xylitol for Healthcare Professionals

In writing this clinical reference, I can think of no better approach than to follow the path I traveled while searching for why the nasal spray I helped develop worked so well. That path is both chronological and topical, but it actually began long before we developed the spray — when my wife, Jerry Bozeman, recognized a connection between chronic early ear infections and children developing learning and behavioral problems in their early school years.

From Jerry Bozeman to a Granddaughter's Ear Infections

Jerry came to special education from an independent-minded direction. Early in her career she began to see a connection in her high-functioning students between their language problems and early childhood ear infections. Ear infections were then seen as a rite of passage — something babies and small children simply had to get through. But every time a child has an ear infection, fluid sits in the middle ear where the ossicles carry sound vibrations to the brain, and fluid dampens those vibrations. When sounds are not clear, children do not make the right connections; learning language is handicapped.

Jerry did not know the mechanism, but she knew the pattern. Over the last decade, physicians have recognized what Jerry saw many years ago. Jerome Klein, co-author of the standard medical text on otitis media in infants and children, lent support when he said, "This Jerry agrees with your Jerry."

The stimulus that led to the search came many years later with a granddaughter's recurrent ear infections and a wife who did not want to risk her future. The Finnish gum study below gave us the idea — and it worked.

Uhari's Finnish Gum Study: 42% Prevention

In Finland, where xylitol is widely used for dental benefits, clinicians observed that children chewing xylitol gum also had fewer ear infections. Matti Uhari and colleagues confirmed this in a landmark double-blind randomized trial published in the British Medical Journal (PMID 8916743).

Among 306 day-care children, those receiving xylitol chewing gum (8.4 g per day) for two months experienced acute otitis media at a rate of 12.1%, compared with 20.8% in the sucrose control group — a difference of 8.7 percentage points. Significantly fewer antimicrobials were prescribed in the xylitol group. The study concluded that xylitol seems to have a preventive effect against acute otitis media.

This was the study that gave us the idea of nasal administration, since that is where the bacteria that cause these infections actually live. Unfortunately, gum used to prevent tooth decay costs about a dollar a day for an effective amount. Using gum to prevent roughly 42% of ear infections would cost a little over $70 to prevent one infection — close to what it costs to treat one.

Direct Nasal Delivery: 90%+ Reduction Under $5/Month

My own experience delivering xylitol directly to the bacteria in the nose results in more than a 90% improvement in symptoms and costs less than five dollars a month — less than six dollars to prevent an infection. It can also be used on infants, like my granddaughter, who do not yet have teeth or the ability to chew gum, where the risks for otitis are substantial.

The anti-adhesive mechanism was clarified by Uhari's group in a follow-up study (PMID 9598780). Exposure of epithelial cells or pneumococci — or both — to 5% xylitol reduced the adherence of pneumococci. Exposure of both cells and bacteria to xylitol reduced adherence of Haemophilus influenzae significantly. The study is important because it shows xylitol works as well when mixed with cells as with bacteria, suggesting the action is not solely on the bacteria themselves.

Sharon's Lectins and the Adherence Model

This sent me looking for how bacteria adhere to our cell surfaces. Nathan Sharon at the Weizmann Institute described lectins — proteins with a sweet tooth that bind carbohydrates reversibly and with high specificity (PMID 8660577). Microbial surface lectins serve as a means of adhesion to host cells — a prerequisite for the initiation of infection. Blocking adhesion by carbohydrates that mimic those to which lectins bind prevents infection.

Sharon and colleagues proposed that proper sugars could inhibit bacterial adherence; mannose, for example, should fill the Type 1 lectins on E. coli and prevent chronic urinary infections. While this therapeutic avenue has mostly been ignored by conventional medicine, it seemed reasonable that xylitol was doing the same kind of thing with our nasal pathogens — an interaction that is not just on the bacteria.

As Itshak Ofek and colleagues document in Bacterial Adhesion to Animal Cells and Tissues, the sugars on our cell surfaces include mannose, galactose, fucose, xylose, and more complex structures. Bacteria bind with lectins specific for particular sugars. Adding the proper sugars competitively inhibits adherence. If bacteria cannot hold on, they cannot cause infection — a point that ties directly to Paul Ewald's work on the evolution of infectious disease.

Biofilm Research from Lubbock

We are increasingly recognizing that biofilms play a role in human disease and are difficult to treat with traditional antibiotic methods. The amount of antibiotic needed to penetrate a biofilm is often about 100 times the normal dose — frequently enough to kill the patient.

Research from the Center for Biofilm Engineering at Montana State University and the Southwest Regional Wound Care Center in Lubbock, Texas, demonstrated that combined lactoferrin and xylitol treatment disrupted the structure of Pseudomonas aeruginosa biofilms and resulted in greater than 2-log reduction in viability (PMID 19010633). Dr. Randall Wolcott's group using the Lubbock Chronic Wound Biofilm model showed that 20% xylitol completely inhibited biofilm formation in a multi-species wound model.

Japanese researchers found that 5% xylitol inhibited glycocalyx production by Staphylococcus aureus, suppressing colonization on atopic dermatitis lesions. The glycocalyx is part of the biofilm bacteria build to protect colonies when they reach a certain size. Xylitol's effect on biofilm formation and adherence represents a fundamentally different approach from escalating antibiotic warfare.

Rhinorrhea as Defense, Not Symptom

By the time I had assembled these references, I found that xylitol's effect on bacteria was only part of the story. Allergies and asthma are, for the most part, independent of bacteria, yet they too are helped by nasal xylitol. Two outside factors helped this search: osteopathic training that says the body heals itself when given the right materials, and a local pharmacist who pointed to two events in the early 1970s — antihistamines and decongestants becoming available over the counter, and the passage of Medicaid and Medicare opening healthcare access — combined with television advertising for cold and allergy pills.

The insight is seeing the runny nose as the body trying to wash out what is bothering it. The common view treats rhinorrhea as a bothersome symptom to turn off. The common-sense view is that rhinorrhea is a defense. Christer Svensson and colleagues at Lund University described mucosal exudation of bulk plasma as a physiological airway tissue response with primarily a defense function (PMID 9517770).

The American Academy of Allergy, Asthma, and Immunology tells us histamine in the back of the nose opens blood vessels so they leak more (providing water for washing), makes more mucus (which holds onto garbage), acts as a local irritant (so we sneeze more), and closes down the airway (to protect the lungs). The concept of asthma as part of this defense is foreign to our current way of seeing.

I documented the epidemiology of these increases in Medical Hypotheses (PMID 11535335): ear infections roughly tripled over 25 years, sinus infections and allergies increased, and asthma paralleled these trends — all beginning in the early 1970s when drugs designed to block the immune system's attempts to wash pollutants from the nasopharynx became widely available.

Practical Dosage for Clinical Use

For prevention and maintenance, the standard regimen is two sprays per nostril in the morning and at night. During acute issues — active infection, significant congestion, or post-exposure to illness — increase frequency to every few hours or at each diaper change for infants in day care.

Look for a spray where xylitol is the first listed ingredient after water, with a concentration of at least 5% and ideally around 11% in saline. The calculated osmolality of an 11% xylitol solution is high enough to reproduce both the washing effect described by Silber and colleagues and the osmolyte effect demonstrated by Zabner (PMID 11005852).

Xylitol is a food substance with two-thirds the calories of sucrose, found in plums and other fruits, with the safest rating from the WHO and FDA as a food additive. The average person produces about 10 grams daily in their own cells. When used intravenously, the usual dosage is 25 mg/kg/hr — far above what any nasal spray delivers.

Case Summaries from Clinical Practice

Case H (infant, 5 months): Placed in day care at five months, breast-fed until age two. Within two months she had an ear infection; four more followed within five months. Parents and day-care workers washed her nose at every diaper change. She had no further ear infections until a new worker was unaware of the routine. Reestablishing regular nasal washing resolved the problem without antibiotics. Over three years she had only two febrile episodes — far below the six URIs per year described as normal for day-care children.

Case B (child, 8 years, asthma): On five medications including regular nasal and systemic steroids, visiting the emergency room every six weeks. After beginning xylitol nasal spray three times daily, material filling the nasopharynx broke loose after about a week — a frightening but productive event. The following week she had no asthma trouble. A week later all asthma medications were stopped. Six months later she was playing basketball and gymnastics without asthma.

Case C (adult, 42 years, diabetes and asthma): Twenty years of both conditions, hospitalized for asthma and pulmonary infections an average of twice annually for ten years. After regular spray use, she experienced no asthma in the ensuing year and required no asthma medication. Peak flow improved from 150–200 L/min to 350 L/min after one year.

Among ten similar children followed in my practice, parents reported 43 ear infections in the five months before treatment (0.86 per month) and only 7 over an average of 11 months follow-up (0.06 per month).

Why This Matters for Healthcare Professionals

Targeting bacteria in ways that are not threatening, as xylitol does, does not seem to produce increased virulence. Dental studies show xylitol selects for friendlier bacteria with decreased cariogenic potential — consistent with Paul Ewald's evolutionary framework. Considering that our major respiratory pathogen, Streptococcus pneumoniae, shares genetic metabolism with Streptococcus mutans, the same approach in our noses is worth serious clinical consideration.

Unfortunately, because xylitol is a food, pharmaceutical interest in nasal delivery has been minimal. Educating patients to choose these less expensive preventive avenues is not well supported by regulatory agencies. Rebuilding our healthcare system to reward prevention over repair is discussed in our book, The Boids and the Bees.

For the full clinical narrative of how this work began, see How We Got Started: From Granddaughter's Ear Infections to Xlear. For why nasal irrigation can worsen chronic problems while xylitol helps, see Why Nasal Irrigation Increases Problems & Xylitol Works Better.